---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-24-002578"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:21:33.772352+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InMed reports positive long-term preclinical AD study results for INM-901 confirming prior pilot data

## Summary
- Long-term (7-month) in vivo study confirms cognitive and memory improvements seen in 3-month pilot using 5xFAD amyloidosis model.
- INM-901-treated AD groups achieved statistical significance in certain behavioral assessments vs. placebo.
- Clear dose response observed across Novel Object Recognition, Open Field, Barnes Maze, and other tests.
- Additional molecular analyses (receptor engagement, neuroinflammation, neurogenesis, neuroprotection) are ongoing.
- CMC/GLP studies being planned to support IND submission; INM-901 targets CB1/CB2/PPAR pathways and penetrates BBB.

## SEC filing metadata
- accession: 0001013762-24-002578
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000101376224002578/0001013762-24-002578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000101376224002578/ea0210292-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-24-002578
- JSON: https://secwatch.observer/filing/0001013762-24-002578.json
- Plain text: https://secwatch.observer/filing/0001013762-24-002578.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.